AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02759549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eSMART-MH
Description: eSMART-MH (Electronic Self-Management Resource Training for Mental Health) is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programmed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. eSMART-MH will be used once a week throughout the duration of radiation treatment.
Study NCT02759549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Mood Tracking (Mood 24/7)
Description: Public social media data posted by participants will be accessed and downloaded to a computer program. Permission for the study team to access this data is optional.
Study NCT02759549 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Theater Testing Workshop
Description: The theater testing workshop consists of one to two one-on-one sessions with study staff during which participants will review a computer program for its content and usability, as well as discuss areas for improvement. Participants will also be asked to complete questionnaires and a attend a brief interview regarding any suggested improvements for the computer program.
Study NCT01921543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITP Stimulation
Description: Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision
Study NCT01921543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CI/BNST stimulation
Description: Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision
Study NCT01921543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No stimulation
Study NCT04687553 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Simplified Evaluation of CONsciousness Disorders (SECONDs)
Description: All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs)
Study NCT03552770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: pro-re-nata repeated single or combined intra-vitreous injection of bevacizumab
Study NCT03645850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vismed gel Multi 0.3% eye drops
Description: Ophthalmic use. Vismed gel Multi 0.3% eye drops. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
Study NCT03645850 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vismed Multi 0.18% eye drops
Description: Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
Study NCT00738075 — intervention group
Intervention type: DEVICE
Intervention: Auditory cue
Description: When device recognizes automatically freezing episode it will generate auditory cue
Study NCT02628093 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: THUNDERBEAT
Description: Tissue dissection and vessels ligation
Study NCT02628093 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LIGASURE
Description: Tissue dissection and vessels ligation
Study NCT01897233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor
Study NCT01897233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Study NCT03749590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Patients receive 2 infusions (10 ml magnesium sulfate added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
Study NCT03749590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NaCl 0,9%)
Description: Patients receive 2 infusions (10 ml NaCl 0.9% added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
Study NCT01315899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12471 30mg
Description: Given as a single dose once during the crossover study as per Williams design
Study NCT01315899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12471
Description: Given as a single dose once during the study as per Williams crossover design
Study NCT01315899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given once as a single dose during the study as per Williams crossover design
Study NCT04157257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF tablet
Description: TDF tablet 300mg QD
Study NCT04157257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF tablet
Description: TDF tablet 300mg QD
Study NCT04157257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir Tablet
Description: Entecavir tablet 0.5mg QD
Study NCT04157257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir Tablet
Description: Entecavir tablet 0.5mg QD
Study NCT04157257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL-007
Description: QL-007 tablets 200mg BID
Study NCT02780947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventricular tachycardia substrate ablation
Description: Study protocol~1. Baseline programmed ventricular stimulation performed from the LV~2. High density endocardial LV mapping using CARTO® 3 System~3. Randomized substrate ablation in half patients. Ablation end-point is considered the elimination of all endocardial late and early potentials (LPs and EPs)~4. Final programmed ventricular stimulation performed from the LV~Programmed ventricular stimulation with up to 4 extrastimuli from LV is performed and repeated at the end of the procedure in patients undergoing substrate ablation.
Study NCT00275275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Requip PR
Description: Requip 24-Hour once a day for one month
Study NCT00275275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirapex
Description: All subjects started the study on Mirapex. They were all then switched to Requip PR based on a conversion factor of 1:3, 1:4 or 1:5.
Study NCT00003531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage IV Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT03753776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills of Radium bromatum
Description: Placebo pills of Radium bromatum will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition
Study NCT03753776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium bromatum pills
Description: Homeopathic Radium bromatum pills will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition
Study NCT03753776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Radium bromatum/Apis mellifica/Belladonna placebo pills
Description: Placebo pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
Study NCT03753776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium bromatum/Apis mellifica/Belladonna pills
Description: Pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
Study NCT02917252 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3-hydroxybuturate
Description: Drink of ketone bodies
Study NCT02917252 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drink of saline
Study NCT03211039 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Genomic sequencing and molecular diagnostic results, if any.
Description: Patients and their families will be randomized to either receive whole genome sequencing or whole exome sequencing.
Study NCT03993327 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iodine I 124 Monoclonal Antibody M5A
Description: Given IV
Study NCT03993327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT02222038 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: skin biopsy
Study NCT02159391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interview
Description: The Brief Motivational Interview implies an empathic interviewing style which (i) recognizes, examines and tries to resolve the patient´s ambivalence to facilitate behavioral change, (ii) promotes self-efficacy, (iii) allows flexibility in strategies, including short-term aims to reduce consumption and decrease damage linked to this consumption (like road accidents), (iv) works to reduce the patient's resistances, and (v) provides individualized feedback, if deemed appropriate, to promote recognition of the problem and cognitive restructuring.
Study NCT03867669 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Open Bay Unit
Description: The eligible infants will be randomized at birth/admission to either the single patient room (experimental) or the open bay unit (Comparator)
Study NCT03867669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single patient room
Description: The eligible infants will be randomized at birth/admission to either the single patient room (experimental) or the open bay unit (Comparator)
Study NCT02160379 — intervention group
Intervention type: OTHER
Intervention: standard test meal
Study NCT03810690 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-3704
Description: mRNA-3704 dispersion for intravenous (IV) infusion
Study NCT03609658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Navigator Pathway
Description: In the Nurse Navigator Pathway, nurse navigators are being used as leverage to: approach qualified patients to initiate advance care planning discussions, schedule advance care planning visit with patients' primary care provider to further discuss advance care planning and to mail advance care planning resources to patients after their initial advance care planning discussion.
Study NCT03609658 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: In the Usual Care arm, there is no approach by nurse navigators to initiate advance care planning discussions and it does not have a structure advance care planning visit. Therefore, no further action is required for the patients who were randomly assigned to the usual care arm.
Study NCT03879148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Erector spinae plane block was performed to the patients under aseptic conditions
Study NCT02594215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7075 (miransertib)
Description: MK-7075 or miransertib (formerly ARQ 092) is small molecule that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a phase I study to determine a recommended dose for subsequent trials, which will determine the efficacy of miransertib in Proteus syndrome.
Study NCT01365403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: Single oral dose, Day 1 of study period 1 and Day 16 of study period 2
Study NCT01365403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbamazepine
Description: multiple oral doses, Days 1-24 of study period 2
Study NCT02306564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: given to patients at high risk for OHSS
Study NCT01282437 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation
Description: * 18 fractions of 2Gy~* 12 fractions of 2.5Gy~* 10 fractions of 3 Gy
Study NCT00269399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin (Xifaxan)
Study NCT00269399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Study NCT06750029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical clown visits
Description: The intervention is 15-minute visits from MCs twice daily during the first two days of admission. The clowns use various techniques to relax the patients (e.g. music, singing, playing, humor, guided imagination) and helpe encourage children to begin drinking and eating on their own.
Study NCT03467724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Radiofrequency (FRF)
Description: Fractional radiofrequency will be delivered to the area of the surgical scar.
Study NCT01325870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACD-CPR
Study NCT01325870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITPR
Description: standard CPR with use of the CirQlator intrathoracic pressure regulator (ITPR)
Study NCT01325870 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: S-CPR
Description: standard manual CPR
Study NCT01325870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impedance Threshold Device (ITD)
Study NCT04547348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab Injection
Description: Injections made subcutaneously per standard description
Study NCT04547348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Denosumab Injection
Description: Injections made subcutaneously per standard description
Study NCT02577523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND0612 (Levodopa/Carbidopa solution)
Description: The total daily dose of levodopa/carbidopa 720/90 mg. Device: CRONO TWIN pump system.
Study NCT02577523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD
Description: The total daily dose levodopa/carbidopa from ND0612 538/67 mg. Morning dose of oral IR-LD/CD 150/15 mg. Device: CRONO TWIN pump system.
Study NCT00697814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Description: Clomiphene 50 mg/day for 12 weeks
Study NCT05386446 — intervention group
Intervention type: DRUG
Intervention: Interferon gamma human recombinant (IFN-G)
Description: nasal form
Study NCT00943605 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel and Traditional Electrosurgery
Description: The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
Study NCT00943605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade
Description: The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
Study NCT00531518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine
Description: Oral, daily, generally at lower than manufacturer's recommendations
Study NCT00531518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational multifamily group treatment
Description: Families and patients are educated on psychobiology of psychosis and trained in coping skills to avoid psychosis by reducing stress and optimizing social environment at home, school, work
Study NCT00531518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported employment and education
Description: Participants are provided direct assistance, guidance and ongoing support to gain employment and succeed in their educational goals.
Study NCT00730002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Angiography (MRA)
Description: As part of the Magnetic Resonance(MR) scan, you will need to lie still on a padded MR table inside the MR machine for about 15 minutes at a time while MR studies are being performed on you. The total time for the clinical portion of the MR study is approximately 35-40 minutes and there will be an additional 30 minutes for the research related MR studies. The total time you will spend on the MR table for this research will seldom be more than one hour.
Study NCT00730002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic resonance imaging
Description: MR spectroscopy
Study NCT00730002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRA
Description: MRA of the brain
Study NCT00730002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRA
Study NCT03164837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-RM26
Description: Single-dose 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans.
Study NCT01961687 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Resorbable Mesh
Description: Phasix Mesh
Study NCT02278458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icotinib
Description: Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
Study NCT02278458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
Study NCT04673708 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: H - Test
Description: Showing different videos for a sexual stimulus and monitor the vitals of each participants to measure any changes can occur with each video.
Study NCT04673708 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: H - Test
Description: Showing different videos for a sexual stimulus and monitor the vitals of each participants to measure any changes can occur with each video.
Study NCT04395248 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exploring potential risk factors of difficult intubation using ultrasound
Description: Before surgery, ultrasound will be used to assess pretracheal soft tissue depth and height and width of tongue base. The distance from the skin to the anterior aspect of the trachea will be measured at three levels: vocal cords, thyroid isthmus, and suprasternal notch. With the patient in a seated position, the convex transducer of a portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be introduced to the skin of the neck in the submental region coronally, immediately cephalad to the body of the hyoid bone, and then in the area between the hyoid bone and the symphysis of the mandible. Maximal width of tongue base, tongue base height, and maximal height of mid-tongue will be measured. The laryngoscopy intubation will be performed using a size-3 or -4 Macintosh (Rüsch Inc., Duluth, GA, USA) blade and a styletted endotracheal tube. The laryngoscopic view will be graded according to Cormack and Lehane's classification with external laryngeal pressure applied.
Study NCT04395248 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial artery catheterization using ultrasound guidance or blind palpation
Description: For all patients, the wrist will be extended and taped to a board to maintain wrist extension. All patients will receive local skin anesthesia at the anticipated puncture site. All radial artery catheterizations will be performed by anesthesiology residents with similar levels of experience in both blind-palpation and ultrasound-guided radial arterial catheterization. In the ultrasound group, a linear vascular probe of portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be applied to the skin to localize the radial artery and a 20-gauge catheter will be inserted distal to the transducer and directed according to the ultrasound image. In the palpation group, the radial artery will be identified by palpation, and the cannula will be directed by continuous or intermittent palpation of arterial pulsation. An attempt is defined as a new penetration of the skin with the needle, followed by an unlimited number of subcutaneous needle redirections.